[1] American Cancer Society. Cancer facts and figures[M]. Atlanta: American Cancer Society, 2013. [2] Kuperman DI, Auethavekiat V, Adkins DR, et al. Squamous cell cancer of the head and neck with distant metastasis at presentation [J]. Head Neck, 2010, 33(5): 714-718. [3] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63(1):10-29. [4] Amornphimoltham P, Patel V, Leelahavanichkul K, et al. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer [J]. Cancer Res, 2008, 68(4): 1144-1153. [5] Easton JB, Houghton PJ. mTOR and cancer therapy [J]. Oncogene, 2006, 25(48):6436-6446. [6] Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents [J]. Nat Rev Drug Discov, 2006, 5(8): 671-688. [7] Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy [J]. Cancer Immunol Immunother, 2008, 57(9): 1271-1278. [8] Ridnour LA, Cheng RY, Switzer CH, et al. Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity [J]. Clin Cancer Res, 2012, 19(6): 1340-1346. [9] Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk [J]. Nat Rev Mol Cell Biol, 2014, 15(3): 155-162. [10] Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer [J]. Cancer Biol Ther, 2003, 2(4 Suppl 1): S169. [11] Huang Z, Wu Y, Zhou X, et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review [J]. Future Oncol, 2015, 11(11): 1687-1699. [12] Fumarola C, Bonelli MA, Petronini PG, et al. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer [J]. Biochem Pharmacol, 2014, 90(3): 197-207. [13] O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity [J]. Nat Rev Immunol, 2013, 13(6): 453-460. [14] Szczepanski MJ, Czystowska, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack [J]. Cancer Res, 2009, 69(7): 3105-3113. [15] Cheng YX, Qi XY, Huang JL, et al. Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer [J]. Eur J Gynaecol Oncol, 2012, 33(3): 291-294. [16] Sun Z, Luo Q, Ye D, et al. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis [J]. Mol Cancer, 2012, 11(1): 33. |